Autoimmune hemolytic anemia: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(Created page with "In hematology, '''{{PAGENAME}}''' is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red...")
 
imported>Robert Badgett
Line 12: Line 12:


==Treatment==
==Treatment==
[[Rituximab]], a [[monoclonal antibody]], was found to be safe by a [[systematic review]] of 21 studies, although only one was a [[randomized controlled trial]]s.<ref name="pmid25497766">{{cite journal| author=Reynaud Q, Durieu I, Dutertre M, Ledochowski S, Durupt S, Michallet AS et al.| title=Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies. | journal=Autoimmun Rev | year= 2014 | volume=  | issue=  | pages=  | pmid=25497766 | doi=10.1016/j.autrev.2014.11.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25497766  }} </ref>


==References==
==References==
<references/>
<references/>

Revision as of 15:00, 22 December 2014

In hematology, Autoimmune hemolytic anemia is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red blood cells."[1]

Classification

Diagnosis

Treatment

Rituximab, a monoclonal antibody, was found to be safe by a systematic review of 21 studies, although only one was a randomized controlled trials.[6]

References